Navigation Links
ImmunoVaccine Technologies Collaborates with NRC Institute for Biodiagnostics Atlantic to measure effectiveness of DepoVax(TM) with novel MRI Imaging
Date:5/20/2009

HALIFAX, May 20 /PRNewswire/ - ImmunoVaccine Technologies Inc. (IVT), a vaccine development company, has announced a collaboration agreement with the National Research Council Institute for Biodiagnostics (NRC-IBD) Atlantic. This collaboration will develop new 3-D MRI technology to track the effect of IVT's DepoVax(TM) technology on reducing tumour growth.

"This research has the potential to deliver extremely sensitive MRI analysis, down to the individual cell level, and we will see, for the first time, our DepoVax(TM) formulation in action," remarked Dr. Marc Mansour, vice president R&D at IVT.

In pre-clinical studies, IVT has shown that DepoVax(TM) vaccines can eradicate cancerous tumors. This new research involves labeling liposomes, suspended in the DepoVax(TM) formulation, with iron-oxide nanoparticles. The 3-D MRI analysis will shed light on the activity of DepoVax(TM) in vivo, and allow the monitoring of tumor elimination in real time.

Current MRI techniques are well established in biomedical research. This research aims at developing highly sensitive and quantitative techniques for monitoring tumor progression and vaccine clearance in vivo.

"This collaboration means that NRC-IBD Atlantic will break new ground in developing novel MRI imaging techniques that will vastly improve the quality of information that may be acquired non-invasively," continued Mansour.

ABOUT IVT

Most recently, ImmunoVaccine Technologies presented significant advancements in its therapeutic cancer, pandemic influenza and Hepatitis B vaccine applications at BIO 2009 international convention www.convention.bio.org.

ImmunoVaccine Technologies Inc., is a privately held, vaccine development company. Through its own biotech research, patented DepoVax(TM) technology, and collaborations with partners, IVT creates vaccines with the potential to help save and improve lives around the world. www.immunovaccine.com.


'/>"/>
SOURCE ImmunoVaccine Technologies Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ImmunoVaccine Technologies Collaborates with NRC Institute for Biodiagnostics Atlantic to measure effectiveness of DepoVax(TM) with novel MRI Imagin
2. ImmunoVaccine Technologies Collaborates with Defence Research & Development Canada to Strengthen Canadas Ability to Deal with Biological Threats
3. ImmunoVaccine Technologies Signs Agreement with National Institutes of Health to Explore Vaccines for HIV and Malaria
4. ImmunoVaccine Technologies Presents at OneMed Place Finance Forum
5. ImmunoVaccine Technologies Broadens Its Patent Protection to Japan
6. ImmunoVaccine Technologies Congratulates Dr. Ramila Philip as One of PAs Best 50 Women in Business
7. ImmunoVaccine Technologies Patents DepoVax(TM) Vaccine Platform
8. ImmunoVaccine Technologies appoints the Honourable Michael Kirby as Chair
9. ImmunoVaccine Technologies Inc. Nears Phase I Clinical Trials with Completion of Scientific Advisory Board
10. GenVault Receives Four Critical U.S. and E.U. Patent Allowances for Key Biosample Management Technologies
11. MedClean Technologies, Inc. Announces Private Offer to Exchange Warrants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
(Date:6/23/2016)... June 23, 2016  The Prostate Cancer Foundation (PCF) is pleased ... and faster cures for prostate cancer. Members of the Class of 2016 were ... Read More About the Class of 2016 PCF Young ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case ... Denmark detail how a patient who developed lymphedema after being treated for breast cancer ... could change the paradigm for dealing with this debilitating, frequent side effect of cancer ...
Breaking Biology Technology:
(Date:6/2/2016)... 2, 2016 The Department of Transport ... the 44 million US Dollar project, for the , ... including Personalization, Enrolment, and IT Infrastructure , to ... production and implementation of Identity Management Solutions. Numerous renowned international ... Decatur was selected for the most compliant ...
(Date:6/2/2016)... , June 2, 2016 ... Manned Platforms, Unmanned Systems, Physical Infrastructure, Support & Other ... provider visiongain offers comprehensive analysis of the ... this market will generate revenues of $17.98 billion in ... acquired DVTEL Inc, a leader in software and hardware ...
(Date:5/24/2016)... facilitates superior patient care by providing unparalleled technology to leaders of the medical imaging ... product recently added to the range of products distributed by Ampronix. Photo ... ... ... News ...
Breaking Biology News(10 mins):